company background image
CHRS logo

Coherus BioSciences NasdaqGM:CHRS Stock Report

Last Price

US$2.58

Market Cap

US$287.3m

7D

-6.5%

1Y

-62.8%

Updated

25 Feb, 2024

Data

Company Financials +

Coherus BioSciences, Inc.

NasdaqGM:CHRS Stock Report

Market Cap: US$287.3m

Coherus BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Coherus BioSciences
Historical stock prices
Current Share PriceUS$2.58
52 Week HighUS$8.65
52 Week LowUS$1.43
Beta0.53
1 Month Change10.26%
3 Month Change32.99%
1 Year Change-62.82%
3 Year Change-84.11%
5 Year Change-82.03%
Change since IPO-79.54%

Recent News & Updates

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Recent updates

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15
Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Coherus: Will Its Chinese Gambit Fail?

May 27

Is Coherus BioSciences (NASDAQ:CHRS) Using Debt In A Risky Way?

Jan 06
Is Coherus BioSciences (NASDAQ:CHRS) Using Debt In A Risky Way?

Coherus BioSciences: Dependable Stock With A Possibility Of Appreciation

Oct 17

Is Coherus BioSciences (NASDAQ:CHRS) Weighed On By Its Debt Load?

Sep 18
Is Coherus BioSciences (NASDAQ:CHRS) Weighed On By Its Debt Load?

Shareholder Returns

CHRSUS BiotechsUS Market
7D-6.5%1.5%1.3%
1Y-62.8%10.5%25.6%

Return vs Industry: CHRS underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: CHRS underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is CHRS's price volatile compared to industry and market?
CHRS volatility
CHRS Average Weekly Movement15.2%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CHRS's share price has been volatile over the past 3 months.

Volatility Over Time: CHRS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010299Denny Lanfearhttps://www.coherus.com

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis.

Coherus BioSciences, Inc. Fundamentals Summary

How do Coherus BioSciences's earnings and revenue compare to its market cap?
CHRS fundamental statistics
Market capUS$287.32m
Earnings (TTM)-US$217.11m
Revenue (TTM)US$211.07m

1.4x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CHRS income statement (TTM)
RevenueUS$211.07m
Cost of RevenueUS$62.63m
Gross ProfitUS$148.45m
Other ExpensesUS$365.55m
Earnings-US$217.11m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.95
Gross Margin70.33%
Net Profit Margin-102.86%
Debt/Equity Ratio-353.9%

How did CHRS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.